Search
Now showing items 11-20 of 45
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
(
Nature Researc
, 2021 , Article)
With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines ...
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.
(
American Medical Association
, 2021 , Article)
The effect of prior SARS-CoV-2 infection on vaccine protection remains poorly understood. To assess protection from SARS-CoV-2 breakthrough infection after mRNA vaccination among persons with vs without prior SARS-CoV-2 ...
Screening the growth inhibition mechanism of sulfate reducing bacteria by chitosan/lignosulfonate nanocomposite (CS@LS) in seawater media
(
Elsevier
, 2021 , Article)
Sulfate-reducing bacteria (SRBs) induced biofilm formation is a global industrial concern due to its role in the development of microbial-induced corrosion (MIC). Herein, we have developed a biodegradable chitosan/lignosulfonate ...
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar.
(
Oxford University Press
, 2021 , Article)
Qatar experienced a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that disproportionately affected the craft and manual worker (CMW) population, who comprise 60% of the total population. This study ...
SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals
(
Elsevier
, 2021 , Article)
The study objective was to the assess level of detectable severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in the urban population of Qatar. Antibody testing was performed on residual blood specimens ...
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
(2021 , Article)
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a ...
Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays.
(
IMR
, 2021 , Article)
Background: High-throughput assays that can infer neutralizing activity against SARS-CoV-2 are of great importance for assessing the immunity induced by natural infection and COVID-19 vaccines. We aimed to evaluate the ...
Epidemiological impact of prioritising SARS-CoV-2 vaccination by antibody status: Mathematical modelling analyses
(
BMJ Publishing Group
, 2021 , Article)
Background Vaccines against SARS-CoV-2 have been developed, but their availability falls far short of global needs. This study aimed to investigate the impact of prioritising available doses on the basis of recipient ...
Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar’s experience
(
International Society of Global Health
, 2022 , Article)
Background: The effective reproduction number, Rt, is a tool to track and understand epidemic dynamics. This investigation of Rt estimations was conducted to guide the national COVID-19 response in Qatar, from the onset ...
Pyridoxine non-responsive p.R336C mutation alters the molecular properties of cystathionine beta-synthase leading to severe homocystinuria phenotype
(
Elsevier
, 2022 , Article)
The prevalence of homocystinuria in Qatar is 1:1800, mainly due to a founder missense mutation p.R336C. • The cystathionine beta-synthase (CBS) R336C mutant was bacterially expressed, purified and its molecular properties ...